The Current Ratio as of September 2024 (TTM) for Pliant Therapeutics, Inc. (PLRX) is 14.47

According to Pliant Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 14.47. This represents a change of -14.64% compared to the average of 16.95 of the last 4 quarters.

Pliant Therapeutics, Inc. (PLRX) Historical Current Ratio (quarterly & annually)

How has PLRX Current Ratio performed in the past?

The mean historical Current Ratio of Pliant Therapeutics, Inc. over the last ten years is 13.83. The current 14.47 Current Ratio has changed 10.37% with respect to the historical average. Over the past ten years (40 quarters), PLRX's Current Ratio was at its highest in in the September 2020 quarter at 27.91. The Current Ratio was at its lowest in in the March 2018 quarter at 0.

Pliant Therapeutics, Inc. (PLRX) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Pliant Therapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Pliant Therapeutics, Inc. (PLRX) Average Current Ratio

How has PLRX Current Ratio performed in the past?

The current Current Ratio of Pliant Therapeutics, Inc. (PLRX) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages

Pliant Therapeutics, Inc. (PLRX) Current Ratio vs. Peers

How is PLRX’s Current Ratio compared to its peers?

Pliant Therapeutics, Inc.’s Current Ratio is less than Relay Therapeutics, Inc. (15.64), greater than Stoke Therapeutics, Inc. (6.67), greater than Black Diamond Therapeutics, Inc. (6.87), greater than Arvinas, Inc. (3.62), greater than 89bio, Inc. (13.92), greater than Madrigal Pharmaceuticals, Inc. (8.72), greater than Arcellx, Inc. (6.01), less than Dyne Therapeutics, Inc. (26.63), greater than Cytokinetics, Incorporated (10.39), less than Revolution Medicines, Inc. (15.42), greater than Syndax Pharmaceuticals, Inc. (10.50), less than Viridian Therapeutics, Inc. (15.82), greater than Inozyme Pharma, Inc. (9.84), greater than TCR2 Therapeutics Inc. (2.96), greater than Atreca, Inc. (1.58), greater than Passage Bio, Inc. (7.67),

Build a custom stock screener for Pliant Therapeutics, Inc. (PLRX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Pliant Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Pliant Therapeutics, Inc. (PLRX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Pliant Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.